Cargando…

PB2670: EQOL-MDS TRIAL: PATIENT-REPORTED OUTCOMES IN PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROMES WITH SEVERE THROMBOCYTOPENIA.

Detalles Bibliográficos
Autores principales:	Oliva, Esther, Iannì, Giuseppe, Riva, Marta, Niscola, Pasquale, Santini, Valeria, Breccia, Massimo, Gaidano, Valentina, Poloni, Antonella, Patriarca, Andrea, Crisà, Elena, Capodanno, Isabella, Salutari, Prassede, Reda, Gianluigi, Sanpaolo, Grazia, Ferrero, Dario, Guarini, Attilio, Tripepi, Giovanni, Castelli, Andrea, Fattizzo, Bruno, Beltrami, Germana, Bocchia, Monica, Molteni, Alfredo, Fenaux, Pierre, Germing, Ulrich, Ricco, Alessandra, Palumbo, Giuseppe A., Impera, Stefana, Renzo, Nicola DI, Buccisano, Francesco, Stamatoullas, Aspasia, Liberati, Anna Marina, Candoni, Anna, Delfino, Ilaria Maria, Cufari, Patrizia, Rizzo, Lorenzo, Latagliata, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429587/ http://dx.doi.org/10.1097/01.HS9.0000977356.44846.cb

Ejemplares similares

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
por: Oliva, Esther Natalie, et al.
Publicado: (2023)

Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)
por: Oliva, Esther Natalie, et al.
Publicado: (2023)

Conceptualization, operationalization, and content validity of the EQOL-questionnaire measuring quality of life and participation for persons with disabilities
por: Jespersen, Louise Norman, et al.
Publicado: (2018)

2670. Sexual Health Evaluation Among People Tested for Mpox in an Urban Health System
por: Jones, Joyce, et al.
Publicado: (2023)

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide
por: Gurnari, Carmelo, et al.
Publicado: (2022)

Urinary metabolite profiling and risk of progression of diabetic nephropathy in 2670 individuals with type 1 diabetes
por: Mutter, Stefan, et al.
Publicado: (2021)

Early lenalidomide treatment for low and intermediate‐1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence
por: Oliva, Esther N., et al.
Publicado: (2015)

Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical–Biological Entity?
por: Campagna, Alessia, et al.
Publicado: (2022)

2670. Clostridioides difficile Infection (CDI) in Solid-Organ (SOT) and Hematopoietic Stem Cell Transplant (HCT) Recipients: A Prospective Multinational Study
por: Blumberg, Emily, et al.
Publicado: (2019)

Management of Acute Promyelocytic Leukemia in the Elderly
por: Lo-Coco, Francesco, et al.
Publicado: (2013)

S173: RETROSPECTIVE STUDY OF LENALIDOMIDE DISCONTINUATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME HARBORING DEL(5Q). A HARMONY ALLIANCE STUDY
por: Crisà, Elena, et al.
Publicado: (2023)

Brief Tale of a Bacteraemia by Rhodococcus equi, With Concomitant Lung Mass: What Came First, the Chicken or The Egg?
por: Savini, Vincenzo, et al.
Publicado: (2011)

A Population-Based Study on Myelodysplastic Syndromes in the Lazio Region (Italy), Medical Miscoding and 11-Year Mortality Follow-Up: the Gruppo Romano-Laziale Mielodisplasie Experience of Retrospective Multicentric Registry
por: Mayer, Flavia, et al.
Publicado: (2017)

ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
por: Buccisano, Francesco, et al.
Publicado: (2022)

Ren W, Ye X, Su H, et al. Genetic landscape of hepatitis B virus–associated diffuse large B-cell lymphoma. Blood. 2018;131(24):2670-2681.
Publicado: (2019)

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience
por: Mossuto, Sandra, et al.
Publicado: (2020)

Atypical Chronic Myeloid Leukemia: Where Are We Now?
por: Crisà, Elena, et al.
Publicado: (2020)

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
por: Breccia, Massimo, et al.
Publicado: (2020)

New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Gallazzi, Marco, et al.
Publicado: (2022)

Fatigue of newly diagnosed patients with acute myeloid leukemia: comparison to the general population and investigation of predictive factors
por: Oswald, Laura B., et al.
Publicado: (2021)

P663: MULTICENTER, PROSPECTIVE AND RETROSPECTIVE OBSERVATIONAL COHORT STUDY OF PONATINIB IN PATIENTS WITH CML IN ITALY: LONG-TERM FOLLOW-UP RESULTS OF THE OITI TRIAL
por: Breccia, Massimo, et al.
Publicado: (2023)

Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia
por: Santoro, Cristina, et al.
Publicado: (2017)

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
por: Giagounidis, Aristoteles, et al.
Publicado: (2013)

Precision Medicine in Systemic Mastocytosis
por: Nicolosi, Maura, et al.
Publicado: (2021)

Case Report: Invasive fungal infection after anti-CD19 CAR-T cell therapy. Implication for antifungal prophylaxis
por: Pennese, Elsa, et al.
Publicado: (2023)

Low Incidence Rate of Opportunistic and Viral Infections During Imatinib Treatment in Chronic Myeloid Leukemia Patients in Early and Late Chronic Phase.
por: Breccia, Massimo, et al.
Publicado: (2011)

Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study
por: Cilloni, Daniela, et al.
Publicado: (2020)

Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials
por: Luciano, Luigia, et al.
Publicado: (2023)

Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia
por: Latagliata, Roberto, et al.
Publicado: (2016)

Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation
por: Puzzolo, Maria Cristina, et al.
Publicado: (2022)

Pro-inflammatory cytokines and bone fractures in CKD patients. An exploratory single centre study
por: Panuccio, Vincenzo, et al.
Publicado: (2012)

Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib
por: Breccia, Massimo, et al.
Publicado: (2017)

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study
por: Iurlo, A., et al.
Publicado: (2023)

Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study
por: Iurlo, Alessandra, et al.
Publicado: (2022)

Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy
por: Efficace, Fabio, et al.
Publicado: (2021)

P505: GIMEMA AML1819 TRIAL: GEMTUZUMAB OZOGAMICIN PLUS INTENSIVE CHEMOTHERAPY IMPACTS ON THE LEVEL OF POST-CONSOLIDATION MEASURABLE RESIDUAL DISEASE (MRD) IN ACUTE MYELOID LEUKEMIA
por: Venditti, Adriano, et al.
Publicado: (2023)

Reliability of flow-cytometry in diagnosis and prognostic stratification of myelodysplastic syndromes: correlations with morphology and mutational profile
por: Guarnera, Luca, et al.
Publicado: (2023)

Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network
por: Specchia, Giorgina, et al.
Publicado: (2021)

Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper
por: Soverini, Simona, et al.
Publicado: (2019)

CD71(−) Alveolar Macrophages in Idiopathic Pulmonary Fibrosis: A Look beyond the Borders of the Disease
por: Puxeddu, Ermanno, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o9u1pj4u6gfsk0bt4ki2eeuq3r